Brelovitug Clears the First Pivotal HDV Gate
Mirum reported that brelovitug met the Phase 3 AZURE-1 primary endpoint in treatment-naive chronic hepatitis delta virus infection. At week 24, 56% of patients receiving 300 mg weekly and 45% receiving 900 mg every…
